Entyvio (vedolizumab) for Inflammatory Bowel Disease
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.662 alerts
Get alerted when Policy MP 5.01.662 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and prior authorization requirements for intravenous and subcutaneous Entyvio used to treat moderate-to-severely active ulcerative colitis or Crohn's disease. Subcutaneous Entyvio is processed under the pharmacy benefit and is subject to applicable formulary and utilization-management requirements.
The policy added a statement that oncology-related use of Entyvio (vedolizumab) is reviewed.
The policy added a statement that subcutaneous Entyvio (vedolizumab) is filled under pharmacy benefit coverage.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.